Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 Pursuant to Regulation 30(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings call and earnings presentation made on August 09, 2022, on Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 2022, is available on the Company's website.
09-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Disclosure Under Regulation 30 (5) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 The Board of Directors at their meeting held on August 08, 2022, has re-constituted the 'Materiality Committee' of the Company with effect from August 08, 2022.
09-08-2022
Bigul

Q1FY23 Quarterly Result Announced for Sequent Scientific Ltd.

 Pharmaceuticals firm Sequent Scientific announced Q1FY23 Result : Revenues at Rs 3,413 Million, up by 6.5%, Latam and Formulations drive growth Commenting on the Company’s performance, Rajaram Narayanan, Managing Director stated “Our overall sales in Q1 FY 23 grew 6.5% compared to corresponding quarter last year, reflecting a strong, resilient performance in a challenging environment. We continue to progress on our strategy to build a sustainable global business in the area of animal health. The Formulations segment grew 19.5% on constant currency basis, driven by a strong performance in Brazil, within the overall Emerging Markets region. The API business results however, are subdued owing to the exceptional impact of the fire incident at our Vizag plant in May, which hampered operations for a few days. We have now restored the operations in full and are geared to complete the backlog of shipments over the rest of the year. The macro environment will remain challenging on account of volatility in currencies and sustained inflationary cost pressures in raw materials and utilities. However, with our concerted efforts in engaging our long-term partners, cautious price increases, and initiatives on cost management, we expect acceleration in the second half of this financial year. We continue to invest in deepening our partnerships with global players, upgrading our manufacturing facilities, expanding the product pipeline and developing our people.” Result PDF
09-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Outcome Of Board Meeting Held On August 08, 2022 Along With Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30, 2022 And Press Release

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022.
08-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 08, 2022 Along With Unaudited Standalone & Consolidated Financial Results For The Quarter Ended June 30, 2022 And Press Release

 Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2022.
08-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 In continuation with our letter dated August 01, 2022, please note the URL for prior (early) registration with revised timing as mentioned in the enclosed letter for the conference call with the Analysts / Investors on Tuesday, August 09, 2022 to discuss Q1FY23 financial results
08-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note that the Company has, as a part of its investors engagement activities, scheduled a conference call with the Analysts / Investors on Tuesday, August 09, 2022, to discuss its Q1FY23 financial results.
01-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended June 30, 2022.

 SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2022.
01-08-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations & Disclosure Requirements) Regulations, 2015

 The Nomination and Remuneration Committee of the Board of Directors, has granted 5,00,000 Class A Options to Mr. P V Raghavendra Rao, Chief Financial Officer of the Company under 'SeQuent Scientific Limited Employee Stock Option Plan 2020' at an exercise price of Rs. 86/- (Rupees Eighty-Six Only) per option which are effective from his date of joining, i.e., July 25, 2022. The said options are convertible into equivalent number of equity shares of Rs. 2/- each of the Company, on exercise. The vesting period of these options is in a phased manner over a period of 5 years and on vesting, is exercisable within a period of 1 (one) year from the date of vesting.
26-07-2022
Bigul

SEQUENT SCIENTIFIC LTD. - 512529 - Statement Of Investor Complaints For The Quarter Ended June 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Krunal ShahDesignation :- Company Secretary and Compliance Officer
18-07-2022
Next Page
Close

Let's Open Free Demat Account